Bausch + Lomb Posts 7% Revenue Growth, Raises 2026 Guidance
Bausch + Lomb reported Q3 2026 revenue of $1.375B, up 7% YoY, and net income of $32M. Adjusted EBITDA was $325M, and adjusted diluted EPS was $0.34. The company raised full-year revenue guidance to $5.45B–$5.55B and adjusted EBITDA guidance to $1.09B–$1.14B. All business segments grew, with notable increases in MIEBO and LUMIFY revenues.
How this was made
The 30-second read
Why it matters
Guidance lift is a fresh, material development that can move the stock.
Market read
Earnings beat and guidance raise provide a clear catalyst for short‑term price movement.
What to watch
Potential supply‑chain constraints or regulatory hurdles for pipeline assets could temper upside.
Background
The article summarizes Bausch + Lomb's Q3 earnings release and updated full‑year guidance.
Ticker impact
Bausch + Lomb reported Q3 2026 results and raised full-year 2026 revenue and adjusted EBITDA guidance.
upward pressure as investors price in higher revenue and EBITDA forecasts
Revenue guidance increased to $5.45‑$5.55B and adjusted EBITDA to $1.09‑$1.14B, a material uplift that typically lifts the stock.
Market effects
Positive for the eye‑care and medical device sector as Bausch + Lomb signals demand growth.
U.S. healthcare equities may see modest upside.
Limited to investors tracking medical‑device and vision‑care stocks.
Counterpoint
If the guidance raise is already priced in, the stock could face a short‑term pullback.
Key entities
- companyBausch + Lomb
Eye‑care and medical‑device manufacturer.
